<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias

Name: Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias
Keywords: Male, Amyloid, Alzheimer’s dementia, Luminescence, Medizinische Fakultät -ohne weitere Spezifikation-, Medizin, Alzheimerkrankheit, Tau-Protein, Enzyme-Linked Immunosorbent Assay, tau Proteins

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 07 Dec 2010Embargo end date: 27 Oct 2021 Germany English Publisher:S. Karger AGJournal:Dementia and Geriatric Cognitive Disorders, volume 31, pages 37-44 (issn: 1420-8008, eissn: 1421-9824,

Authors: Bibl, Mirko; Mollenhauer, Brit; Lewczuk, Piotr; Esselmann, Hermann; Wolf, Stefanie; Otto, Markus; Kornhuber, Johannes; +11 Authors

Bibl, Mirko; Mollenhauer, Brit; Lewczuk, Piotr; Esselmann, Hermann; Wolf, Stefanie; Otto, Markus; Kornhuber, Johannes; Wiltfang, Jens; Rüther, Eckart; Bibl, Mirko; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Mollenhauer, Brit; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Lewczuk, Piotr; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Esselmann, Hermann; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Wolf, Stefanie; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Otto, Markus; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Kornhuber, Johannes; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Rüther, Eckart; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany; Wiltfang, Jens; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany;

doi: 10.1159/000322370 , 10.18725/oparu-39329

pmid: 21135556

Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias

- Summary
- Subjects
- Related research
  (42)
- Metrics

tips_and_updates
Recommended

Abstract

Background/Aims: We determined cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ)1–38, Aβ1–40, Aβ1–42, total tau and phospho-tau (p-tau) in order to study their differential expression in frontotemporal dementia (FTD, n = 25) and primary progressive aphasia (PPA, n = 12) as compared to Alzheimer’s dementia (AD, n = 25) and nondemented controls (n = 20). Methods: Commercially available ELISA and electrochemiluminescence methods were applied. Results: High CSF p-tau and low ratios of Aβ1–42/Aβ1–40 and Aβ1–42/Aβ1–38, respectively, were specific for AD. CSF Aβ1–38 was reduced in FTD as compared to each of the other diagnostic groups, including PPA. CSF tau and p-tau levels were elevated in PPA as compared to FTD. Conclusion: This is the first detailed report on biomarker patterns in PPA, indicating distinct CSF biomarker patterns in FTD and PPA as major subgroups of frontotemporal lobar degeneration. The diagnostic and pathophysiological implications of our results warrant further studies on larger and neuropathologically diagnosed patient populations.

Country

Germany

Related Organizations

University of Göttingen
Germany
Kliniken Essen-Mitte
Germany
Ludwig-Maximilians-Universität München
Germany
University of Ulm
Germany
University of Erlangen-Nuremberg
Germany

View all View all

Keywords

Male, Amyloid, Alzheimer’s dementia, Luminescence, Medizinische Fakultät -ohne weitere Spezifikation-, Medizin, Alzheimerkrankheit, Tau-Protein, Enzyme-Linked Immunosorbent Assay, tau Proteins, Amyloid <beta->, Neuropsychological Tests, tau proteins, Amyloid-�� peptides, Alzheimer Disease, Primary progressive aphasias, Humans, info:eu-repo/classification/ddc/610, Aged, Frontotemporale Demenz, Amyloid-β peptides, Amyloid beta-Peptides, Amyloid beta-peptides, Biomarker, Middle Aged, p-Tau, Peptide Fragments, Alzheimer��s dementia, Aphasia, Primary Progressive, Phenotype, Cerebrospinal fluid, Frontotemporal Dementia, Liquor cerebrospinalis, Female, Alzheimer disease, DDC 610 / Medicine & health, Frontotemporal dementia, Biomarkers, ddc: ddc:610

Filter by relation

All relations

arrow_drop_down

42 Research products, page 1 of 5

Distinct Functional Effects of Human 5-HT4 Receptor Isoforms on β-Amyloid Secretion
2008IsAmongTopNSimilarDocuments
Neuropsychiatric Correlates of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
2008IsAmongTopNSimilarDocuments
Schisandrin Restores the Amyloid β-Induced Impairments on Mitochondrial Function, Energy Metabolism, Biogenesis, and Dynamics in Rat Primary Hippocampal Neurons
2021IsAmongTopNSimilarDocuments
Study of Neuronal Apoptosis and Changes in Expression of the Proteins Related to the Mitochondrial Pathway after Aβ1–42 Injection in the Rat Hippocampus
2008IsAmongTopNSimilarDocuments
Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia
2002IsAmongTopNSimilarDocuments
Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia
2020IsAmongTopNSimilarDocuments
Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays
2019IsAmongTopNSimilarDocuments
Microtubule-associated protein
2017IsRelatedTo
Microtubule-associated protein
2017IsRelatedTo
Further Evidence on Mitochondrial Targeting of β-Amyloid and Specificity of β-Amyloid-Induced Mitotoxicity in Neurons
2011IsAmongTopNSimilarDocuments

chevron_left
1
2
3
4
5
chevron_right

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	49
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%

Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β<sub>38/40/42</sub> in Frontotemporal Dementias and Primary Progressive Aphasias

Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β<sub>38/40/42</sub> in Frontotemporal Dementias and Primary Progressive Aphasias

42 Research products, page 1 of 5

Distinct Functional Effects of Human 5-HT<sub>4</sub> Receptor Isoforms on β-Amyloid Secretion

Neuropsychiatric Correlates of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease

Schisandrin Restores the Amyloid β-Induced Impairments on Mitochondrial Function, Energy Metabolism, Biogenesis, and Dynamics in Rat Primary Hippocampal Neurons

Study of Neuronal Apoptosis and Changes in Expression of the Proteins Related to the Mitochondrial Pathway after Aβ<sub>1–42</sub> Injection in the Rat Hippocampus

Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid<sub>1–42</sub> in the Differentiation between Alzheimer’s Disease and Vascular Dementia

Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia

Long-Term Storage Effects on Stability of Aβ<sub>1–40</sub>, Aβ<sub>1–42</sub>, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays

Microtubule-associated protein

Microtubule-associated protein

Further Evidence on Mitochondrial Targeting of β-Amyloid and Specificity of β-Amyloid-Induced Mitotoxicity in Neurons